Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Quadrivalent Influenza Vaccine in Healthy People
NCT02708173Phase 1Completed
- Sponsor
- Beijing Chaoyang District Center for Disease Control and Prevention
- Start
- Mar 2016
- Primary completion
- Mar 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of quadrivalent influenza virus vaccine in influenza (2 arms), sponsored by Beijing Chaoyang District Center for Disease Control and Prevention. Primary endpoint: The rate of adverse reactions of Quadrivalent Influenza Virus Vaccine at 3 months. Started Mar 2016; status: completed.
02
Drugs
quadrivalent influenza virus vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02708173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02708173.